Cryotherapy in Treating Patients With Primary Lung Cancer or Lung Metastases That Cannot Be Removed By Surgery
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00303901|
Recruitment Status : Completed
First Posted : March 17, 2006
Results First Posted : February 23, 2015
Last Update Posted : February 23, 2015
RATIONALE: Cryotherapy kills tumor cells by freezing them. This may be an effective treatment for primary lung cancer or lung metastases that cannot be removed by surgery.
PURPOSE: This clinical trial is studying how well cryotherapy works in treating patients with primary lung cancer or lung metastases that cannot be removed by surgery.
|Condition or disease||Intervention/treatment||Phase|
|Lung Cancer Metastatic Cancer||Procedure: cryosurgery Procedure: positron emission tomography||Not Applicable|
- Estimate the local and distant failure rates after percutaneous thoracic cryotherapy (PTC) in patients with unresectable primary lung cancer or lung metastases.
- Estimate rates of PTC complications and adverse reactions.
- Determine the correlations between procedural parameters and follow-up imaging parameters, with the latter being used as surrogates of local and/or distant treatment failure.
OUTLINE: Patients undergo CT-guided percutaneous thoracic cryotherapy over 2 hours under local or general anesthesia. Grouped cryoprobes are inserted into the tumor, utilizing a freeze-thaw-freeze cycle, creating cytotoxic temperatures (less than -20°C to -40°C) that encompass the entire anticipated tumor volume.
Patients undergo positron emission tomography at baseline and after cryotherapy to assess tumor standard uptake variable.
After completion of study treatment, patients are followed at 1, 3, 6 and 12 months.
PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||40 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Percutaneous Thoracic Cryotherapy (PTC) for Inoperable Primary Lung Cancer and Metastatic Management|
|Study Start Date :||November 2005|
|Actual Primary Completion Date :||July 2011|
|Actual Study Completion Date :||July 2011|
cryoprobe is placed in the proper position using CT imaging guidance, and as internal tissue is being frozen, the physician avoids damaging healthy tissue by viewing the movement of the probe on CT images transmitted to a monitor similar to a television screen. Living tissue, healthy or diseased, cannot withstand extremely cold conditions.
|Procedure: cryosurgery Procedure: positron emission tomography|
- Local Failure Rates by CT Scan [ Time Frame: at 3, 6, and 12 months ]
- Distant Failure Rate [ Time Frame: at 3, 6, and 12 months ]
- Rate of Complications and Adverse Reactions by Occurrences of Toxicities [ Time Frame: at 3, 6, and 12 months ]
- Correlate Procedural Parameters and Follow-up Imaging Parameters [ Time Frame: at 3, 6, and 12 months ]
- Point and Exact Confidence Interval Estimates of Patients Who Undergo Multiple Cryotherapy Procedures [ Time Frame: 12 months after the last patient was enrolled ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00303901
|United States, Michigan|
|Barbara Ann Karmanos Cancer Institute|
|Detroit, Michigan, United States, 48201-1379|
|Study Chair:||Peter J. Littrup, MD||Barbara Ann Karmanos Cancer Institute|